Navigation Links
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Date:3/19/2009

re is confidence that the two products fall within a range of 80-125% of one another for each variable.

In this study, both SBS-1000 and Humulin(R) R were bioequivalent to Humulin(R) S with respect to total insulin exposure, maximum concentration of insulin and total glucose infused. The only anomalous result from this trial relates to some of the Humulin(R) S data. Neither SBS-1000 nor Humulin(R) R was bioequivalent to Humulin(R) S with respect to the maximum glucose infusion rate. This difference between the two reference standards (Humulin(R) R and Humulin(R) S) was not expected in such a trial and relates, at least in part, to random outliers that occurred in the Humulin(R) S arm and higher overall variability for this endpoint in the trial.

While final analyses regarding safety data are not yet available, the adverse events observed were typical for a study involving recombinant human insulins. The most common events were insulin injection site reactions, pain at the site of glucose infusion, headache and dizziness, with all similar rates of occurrence for both Humulins and SBS-1000. There were no serious adverse events and there were no events indicative of a systemic allergic response to any of the insulins.

"This is the first time one of our plant-derived recombinant proteins has been studied in humans and we were gratified to see that SBS-1000 performed in an equivalent manner to marketed recombinant human insulin with respect to pharmacologic activity and tolerability," said Dr. Maurice Moloney, Chief Scientific Officer and founder of SemBioSys. "We would anticipate that full results of this trial will be submitted to a future scientific conference once all data have been analyzed."

"These results represent a significant milestone for SemBioSys. We have now demonstrated that we can consistently obtain regulatory approval to grow our insulin safflower crops. We have shown that we can extract, purify and formulate insulin from
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys announces senior management changes
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
5. SemBioSys announces second quarter 2008 financial and operational results
6. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
9. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
10. SemBioSys announces first quarter 2008 financial and operational results
11. SemBioSys receives milestone payments from AVAC Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... WASHINGTON , May 5, 2015  Indianapolis-based ... adoption of its innovative line of products including ... solution for atraumatically accessing deep-seated brain abnormalities and ... have been completed at more than 50 institutions ... The technology has also been included in 12 ...
(Date:5/4/2015)... YORK , May 4, 2015 ... for granted. But for certain infants with rare, ... death are stark consequences of their impaired immune ... Medical Center have identified an important role for ... resulting from Mycobacterium tuberculosis, the bacterium causing tuberculosis ...
(Date:5/4/2015)... 2015   St. Jude Children,s Research Hospital ... tool for finding genetic alterations that play an ... to identify with whole-genome sequencing. The findings appear ... . The tool is an algorithm ... Regression Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... May 4, 2015  Traverse Biosciences announced today ... and development agreement (CRADA) with Aratana Therapeutics Inc. ... of TRB-N0224 for the treatment and control of ... cats.  Traverse Biosciences has also granted Aratana an ... and control of periodontal disease in companion animals, ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4
... was the soccer-ball-shaped molecules dubbed buckyballs. Then it was ... in physics and nanotechnology is graphene: a remarkably ... rings much like molecular chicken wire. Not ... also is 10 times stronger than steel and it ...
... Conn., Nov. 17 Doctors Research Group, Inc. announced ... U.S. Food and Drug Administration (FDA) to market KRYPTONITE(TM) ... represents a major advancement in treating cranial defects due ... low exotherm cement and bone void filler approved for ...
... Nov. 17 Merriman Curhan Ford Group, Inc. (Nasdaq: ... (OTC Bulletin Board: PYMX) $20.7 million registered public offering of ... per unit, consist of one share of PolyMedix common stock ... share of PolyMedix common stock at $1.25 per share. , ...
Cached Biology Technology:New study confirms exotic electric properties of graphene 2New study confirms exotic electric properties of graphene 3Doctors Research Group Receives FDA Clearance for U.S. Distribution of KRYPTONITE(TM) Bone Cement 2Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... the Huntsman Cancer Institute at the University of Utah discovered ... to 30 percent of human tumors. , Called Ras, normal ... communication among cells. When mutated, however, Ras is an "oncogene" ... growth of cancers in the pancreas, colon and lung, as ...
... has shown that for some fish species, females prefer ... for mating. That does not exclude males with an ... the larger-endowed males in a predator-laden environment because they ... larger genitalia, who lose out because the size of ...
... world are breathing a sigh of relief, as ... harvested for their natural disease-fighting substances. Scientists recently ... symbiotically inside the sea squirt, actually produces the ... used in cancer treatment. , Despite decades of ...
Cached Biology News:Scientists inhibit cancer gene 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
... Human CD66 acd Recognizes human ... neutrophils and cells in some cases ... with transfectants containing BGPa, NCA and ... Immunogen: Human ...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Request Info...
Biology Products: